Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

ion, the reductions in A1C and FPG with JANUVIA compared to placebo were generally similar to those observed in other monotherapy studies. (See Clinical Pharmacology (12.3).) 14.2 Combination Therapy Combination Therapy with Metformin A total of 701 patients with type 2 diabetes participated in a 24-week, randomized, double-blind, placebo-controlled study designed to assess the efficacy of JANUVIA in combination with metformin. Patients already on metformin (N=431) at a dose of at least 1500 mg per day were randomized after completing a 2-week single-blind placebo run-in period. Patients on metformin and another antihyperglycemic agent (N = 229) and patients not on any antihyperglycemic agents (off therapy for at least 8 weeks, N = 41) were randomized after a run-in period of approximately 10 weeks on metformin (at a dose of at least 1500 mg per day) in monotherapy. Patients were randomized to the addition of either 100 mg of JANUVIA or placebo, administered once daily. Patients who failed to meet specific glycemic goals during the studies were treated with pioglitazone rescue. In combination with metformin, JANUVIA provided significant improvements in A1C, FPG, and 2-hour PPG compared to placebo with metformin (Table 3). Rescue glycemic therapy was used in 5% of patients treated with JANUVIA 100 mg and 14% of patients treated with placebo. A similar decrease in body weight was observed for both treatment groups. Table 3 Glycemic Parameters at Final Visit (24-Week Study) for JANUVIA in Combination with Metformin+ ---------------------------------------------------------------------- JANUVIA Placebo + 100 mg + Metformin Metformin ----------------------------------------------------------- --------- A1C (%)
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:9/23/2014)... Research and Markets has announced ... Markets" report to their offering. ... - including products to treat cancer, diabetes, HIV/AIDS and ... the final stages of clinical drug testing for new ... production capital to upscale while anticipating FDA or EMA ...
(Date:9/23/2014)... -- SiteOne Therapeutics Inc. today announced the completion of its ... Management and Biobrit LLC, with additional investors Mission Bay ... financing positions SiteOne to advance its oral Na V ... its technology platform for long-acting local analgesics, pain diagnostics ... the financing, Lowell Sears (Sears Capital Management) ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... Inc. (NTI(R)) (Nasdaq: NTII ), today announced ... monitoring board (DSMB) has,recommended continuation of the company,s ... brief intravenous infusion of Viprinex(TM) (ancrod),started within 6 ... 3,months. This is the fifth DSMB meeting for ...
... Genmab has,announced that HuMax-EGFr (zalutumumab) inhibits epidermal ... factor receptor (EGFr),molecules into a very compact, ... central to its role in signaling, and ... of cancer cell growth., Genmab A/S ...
Cached Medicine Technology:Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod) 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 3
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... September 5, that its Private Label Jalapeno Bagels are ... small stones. Publix Jalapeno Bagels were sold ... bakery department. , Taking into consideration the latest ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- A test used to diagnose ... where certain lung infections are more common, a new analysis ... is through the use of what,s known as functional imaging. ... FDG-PET is used, according to the study authors. Cancerous ... parts of the lungs that don,t have cancer, according ...
(Date:9/23/2014)... September 23, 2014 Grinnell Mutual ... improvement projects in the Midwest. Working Together Making ... three non-profit organizations with projects positively impacting their ... rural marketplace make their communities a better places,” ... and Community Relations Barb Baker. “Their leadership—as coaches, ...
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... Texas (PRWEB) September 23, 2014 ... for allergic rhinitis (AR) is highly fragmented, ... different SIT formulations available, under different regulatory ... between markets. Europe has the most developed ... (SLIT), and allergen immunotherapy tablets (AITs) all ...
Breaking Medicine News(10 mins):Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2Health News:Note to young men: Fat doesn't pay 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... House ceremony next month, Thomas L. Kash, PhD, assistant professor ... for Alcohol Studies at the University of North Carolina at ... Career Award for Scientists and Engineers (PECASE). , This is ... science and engineering professionals in the early stages of their ...
... in the October 2011 issue of The FASEB ... "healthy" ingredient in red wine, stops breast cancer cells ... This discovery, made by a team of American and ... is able to counteract the malignant progression since it ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Sept. 28 ... advanced Alzheimer,s or other form of severe dementia will be shuttled ... months of life, a new U.S. study shows. The ... Depending on where a patient lives, as many as ...
... the British Journal of Sports Medicine * highlights the injury ... chance of a school player suffering an injury during a single ... research, could be as high as 90 per cent. The ... City University say there is an urgent need to inform children, ...
... with dementia can still make decisions in their everyday lives ... as their condition advances. This is one of the preliminary ... and Social Research Council (ESRC) into how married couples living ... study is investigating how couples make decisions over issues such ...
... dose of the hallucinogen psilocybin, the active ingredient in ... measureable personality change lasting at least a year in ... new study, according to the Johns Hopkins researchers who ... part of the personality known as openness, which includes ...
Cached Medicine News:Health News:UNC researcher to receive highest US honor for early career science professionals 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 3Health News:Academic issues warning on schoolboy rugby 2Health News:Living with dementia and making decisions 2Health News:Single dose of hallucinogen may create lasting personality change 2Health News:Single dose of hallucinogen may create lasting personality change 3
Thornton titanium curved suture tying forceps, 4"....
Round handle McPherson angled tying forceps with 10 mm tips and 5 mm titanium coated platforms. Length 110 mm....
Tennant curved tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano straight tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Medicine Products: